Irinotecan 100mg
        
            
            
                | Product Overview | 
                        | Generic Name | Irinotecan 100mg | 
                                    | Brand Name(s) | Campto® (Pfizer), Irinotel® | 
                                    | Form | Inj Vial | 
                                    | Strength | 100 mg | 
                                    | Therapeutic Class | Topoisomerase I inhibitor | 
                                    | ATC Code | L01XX19 | 
            
            
            
                | Manufacturing & Regulatory | 
                        | Manufacturer | Multiple Firms | 
                                    | Country | India | 
                                    | GMP Compliance | WHO-GMP certified facility | 
                                    | DMF/CEP | Unknown – request from mfg | 
                                    | COFEPRIS | Registered – exact Clave pending | 
                                    | Free Sale Certificate | Yes | 
            
            
            
                | Logistics & Export | 
                        | MOQ | 10 vials | 
                                    | Shelf Life | 12-24 Months | 
                                    | Storage | 2–8 °C, cool & dry | 
                                    | Incoterms | Exworks, DDP, FOB | 
                                    | Lead Time | 2 weeks | 
            
            
            
                | Documentation | 
                        | Certificate of Analysis (COA) | Manufacturer provides COA | 
                                    | SDS | Available on request | 
                                    | CTD Summary | Available upon purchase with fee | 
            
        
                    
                
Description
                Indications & Usage: Antineoplastic agent in FOLFIRI regimens for metastatic colorectal cancer; causes diarrhea and neutropenia; blocks topoisomerase I preventing DNA replication. Used in FOLFIRI, second-line colorectal, other GI tumors; diarrhoea and myelosuppression risk.            
        
       
            Request for Quote